N-Arylphthalimides (1−10P) derived from thalidomide
by insertion of hydrophobic groups were evaluated for
anti-inflammatory activity, and (4-(1,3-dioxo-1,3-dihydro-2Hisoindol-
2-yl)-N′-[(4-ethoxyphenyl)methylidene]benzohydrazide
6P was identified as a promising anti-inflammatory agent. Further
testing confirmed that compared with the control, 6P treatment
resulted in a considerable decrease in CD4+, NF-κB p65+, TNF-
α+, IL-6+, GITR+, and IL-17+ cell populations and an increase in